Authors:
Jignesh Rawal, Shishanka Wangnoo
Download free PDF
U.S. Female External Catheter Market Size & Share 2026-2035
Report ID: GMI12922
|
Published Date: September 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Download Free PDF
Explore Our Licensing Options:
Download Free PDF
U.S. Female External Catheter Market
Get a free sample of this report
Get a free sample of this report U.S. Female External Catheter Market
Is your requirement urgent? Please give us your business email
for a speedy delivery!
U.S. Female External Catheter Market Size
The U.S. female external catheter market was estimated at USD 306.8 million in 2025 and is projected to reach USD 526.8 million by 2035, at a 5.7% CAGR from 2026 to 2035. Growth reflects a shift from managing leakage solely through absorbent products or indwelling catheters toward non-invasive urine collection options that can support skin management, caregiver workflows, and catheter-avoidance protocols.
U.S. Female External Catheter Market Key Takeaways
Market Leader: Becton, Dickinson and Company led with over 60% market share in 2025.
Leading Players: Top 5 players in this market include Becton, Dickinson and Company, Hollister, Stryker, which collectively held a market share of 82% in 2025.
Female external catheters are worn externally around the urethral area and route urine to a drainage container without urethral insertion. Their commercial relevance is strongest where incontinence is persistent, mobility is limited, or an indwelling urinary catheter would create avoidable infection-control exposure. Clinical need is substantial: an estimated 61.8% of U.S. adult women, approximately 78.3 million individuals, experience urinary incontinence, with 32.4% reporting symptoms at least monthly and 9.8% reporting daily symptoms. The Urology Care Foundation separately estimates that urinary incontinence affects 30-40% of women.
Demand is not distributed evenly across care settings. Among Medicare fee-for-service beneficiaries, incontinence prevalence reached 24.5% in home health, 20.6% in skilled nursing facilities, and 16.6% in nursing homes; incontinent beneficiaries were also substantially more likely to experience urinary tract infections, dermatitis, and falls.
Medicare coverage creates a meaningful, but bounded, access pathway. Local Coverage Determination L33803 covers female external urinary collection devices as alternatives to indwelling catheters for beneficiaries with permanent urinary incontinence, subject to documentation requirements and restrictions on concurrent indwelling-catheter use,. The policy therefore supports recurring utilization among qualifying patients without making the category universally reimbursable for every episode of leakage or short-term urinary management.
GMI Analyst View
Our market estimates show the U.S. market rising from USD 318.7 million in 2026 to USD 526.8 million in 2035, but the underlying demand case is more selective than the headline trajectory suggests. High female incontinence prevalence creates a large clinical need pool, while the heaviest operational burden is concentrated in home health, skilled nursing, and nursing-home environments where continence care intersects with skin protection, caregiver time, and infection exposure,.
Coverage policy narrows that broad need pool into an addressable reimbursed segment. Medicare recognizes female external collection devices as an alternative for beneficiaries with permanent urinary incontinence, yet requires documented permanence and excludes simultaneous indwelling-catheter use,. Growth therefore depends on converting clinically appropriate patients through documentation, discharge planning, and product-fit workflows rather than simply expanding awareness.
The market's 5.7% forecast CAGR is consequently tied to care-intensity economics. Suppliers that demonstrate reliable urine capture and tolerability in institutional and home-based settings can participate in recurring disposable consumption, whereas products positioned only as convenience accessories may face weaker reimbursement conversion and lower clinician advocacy.
Key Drivers
Increasing prevalence of urinary incontinence
Urinary incontinence enlarges the clinical population requiring practical urine-management options, but symptom severity and setting determine conversion into external-catheter demand. National Health and Nutrition Examination Survey data found stress urinary incontinence in 37.5% of affected women, mixed incontinence in 31.3%, and urgency incontinence in 22.0%; 22.1% of U.S. adult women had moderate-or-worse symptoms. The clinical burden becomes commercially more significant in home health and long-term care, where continence management is recurrent and associated with elevated urinary tract infection, dermatitis, and fall risk. External systems are positioned to address this higher-intensity subset without urethral insertion.
Growing awareness about female incontinence management
Awareness supports adoption when it reframes incontinence from an absorbent-product issue into a clinical management problem involving dignity, skin condition, mobility, and caregiver workload. The category benefits from greater recognition that women with urgency, mixed symptoms, mobility limitations, or post-procedure needs may require more active urine collection than pads alone provide. That education is most commercially effective when embedded in discharge protocols, continence programs, and caregiver training rather than directed solely at consumers.
Technological advancements in product
Product development is expanding the category beyond basic external collection through softer contact surfaces, improved tubing configurations, skin-compatible materials, and designs intended to remain secure during repositioning. Evidence from intensive-care implementation shows why performance improvements matter operationally: following female external urinary catheter introduction across nine ICUs, female catheter-associated urinary tract infection rates declined from 3.14 to 1.42 per 1,000 indwelling-catheter days, while indwelling-catheter use declined despite growth in ICU patient-days. A broader meta-analysis found that protocol-adherent implementation was associated with a 54% reduction in catheter-associated urinary tract infection rates, although the overall pooled reduction was not statistically significant because of study heterogeneity. Technology creates demand when it is paired with a protocol that changes clinical practice.
Rise in chronic conditions
Chronic illness, functional dependence, neurological conditions, and age-related urgency symptoms increase the likelihood that urine management becomes a recurring care task. In a nationally representative analysis of U.S. women, urgency and mixed urinary incontinence were most prevalent among women aged 60 years and older. This pattern favors external collection products in settings where repeated leakage management, overnight care, and limited mobility impose sustained labor demands. The opportunity is strongest when a device can reduce the need for indwelling-catheter placement without creating a new burden of repositioning, leakage, or skin irritation.
Key Restraints
Risk of infections and skin irritation
External collection avoids urethral insertion, but it does not eliminate the need for rigorous skin assessment, fit verification, moisture management, and device-change discipline. Reusable-device adherence challenges observed in a 12-month multicenter catheterization trial illustrate the importance of usability: discontinuation was 39.0% with reusable products versus 26.6% with single-use products, with reduced ease of use and urethral irritation among reported reasons for stopping. The trial evaluated intermittent catheterization rather than female external catheters, so it should not be treated as direct product evidence; it nevertheless signals that tolerability and workflow friction can limit repeat use in urine-management categories.
High cost associated with advanced catheter
Advanced external systems must justify their procurement cost against absorbent alternatives, staff time, and avoided complications. Medicare coverage is available only within defined permanent-incontinence criteria and billing conditions, leaving providers and patients to manage access barriers outside that pathway,. The economic argument is strongest in facilities where indwelling-catheter avoidance has measurable consequences: Agency for Healthcare Research and Quality data show that hospitalization costs associated with catheter-associated urinary tract infection can be materially higher than stays without the infection, while Medicare analyses have identified both additional costs and length of stay for ICU- and non-ICU-acquired cases,. Suppliers must translate that system-level value into credible unit-level purchasing cases.
GMI Analyst View
Our analysis indicates that the next adoption phase will be led by institutions that can connect external-catheter use to a defined catheter-avoidance protocol rather than treating the product as a stand-alone supply item. In protocol-adherent studies, female external urinary-wicking devices were associated with a 54% reduction in catheter-associated urinary tract infection rates, and ICU implementation evidence showed lower female infection rates alongside reduced indwelling-catheter days,. These results support a clinical-economic proposition, but only when training, patient selection, and monitoring are part of deployment.
The cost of failure to prevent catheter-associated infection makes that proposition material. Infection-related stays can carry substantially higher hospital costs, and Medicare analyses identify additional expense and length of stay for both ICU and non-ICU cases,. That burden gives infection prevention teams a reason to fund external collection systems when they can displace avoidable indwelling use.
Adoption remains constrained by reimbursement boundaries and product execution. Medicare eligibility is condition-specific, while tolerability and ease-of-use issues can interrupt repeat utilization,,. Commercial momentum will therefore depend on evidence packages that demonstrate clinical fit, skin-management performance, and staff workflow reliability in the patient cohorts for whom coverage and avoided-cost logic are aligned.
U.S. Female External Catheter Market Segment Analysis
By Product Type
Disposable products accounted for 92.4% of the market in 2025 and are projected to reach USD 492 million by 2035, expanding at a 5.9% CAGR. Their dominance reflects infection-control preferences and the avoidance of cleaning, reprocessing, and cross-use uncertainty in hospitals, post-acute facilities, and home-care settings. Single-use formats also fit recurring supply models and can reduce the training burden associated with maintenance.
Reusable products generated USD 23.2 million in 2025. Their position depends on situations where durability and lower replacement frequency are valued, but adoption is constrained by cleaning requirements and the risk that convenience declines over time. The broader compliance evidence from reusable catheterization products reinforces the commercial advantage of designs that minimize patient handling and maintenance complexity.
By Incontinence Type
Overactive bladder and urge incontinence represented USD 128.5 million in 2025, making this the leading incontinence-type segment. Urgency and mixed urinary incontinence rise in older age groups, aligning the segment with Medicare beneficiaries, home-health patients, and residents of skilled care environments. The commercial need is often episodic but recurrent: users require a non-invasive management option during periods of limited mobility, overnight care, or frequent urgency.
Stress urinary incontinence accounted for USD 96.1 million in 2025. Leakage associated with exertion presents a different use case, with greater emphasis on discretion, mobility, and secure fit during daily activities. External collection can serve selected users who need active urine management, although product design must avoid creating bulk or attachment issues that conflict with ambulatory use.
Other incontinence types include mixed, functional, overflow, and condition-specific presentations. This segment rewards suppliers that can differentiate patient-selection protocols rather than promote a single device configuration across clinically dissimilar users.
By Material
Silicone generated USD 122.6 million in 2025 and is expected to outpace latex as material choice increasingly reflects skin compatibility and infection-control priorities. Silicone's flexibility and non-allergenic profile support prolonged skin contact, while clinical catheter studies have found lower bacterial colonization and biofilm-forming properties for pure silicone than silicone-coated latex.
Latex accounted for USD 88.5 million in 2025. It retains relevance where elastic fit and lower material cost are priorities, particularly for shorter-duration use. However, allergy considerations and material-performance concerns limit its strategic position. A review of 26 clinical studies associated siliconised latex with higher urinary tract infection risk and noted that latex should be avoided where allergy risk is relevant; the review also identified greater bacterial adherence potential associated with latex's hydrophobic properties.
PVC and other materials serve narrower design, cost, and durability requirements. Their commercial potential depends less on broad material substitution and more on whether they enable differentiated fit, fluid handling, comfort, or disposal characteristics without compromising skin compatibility.
By Application
Urinary incontinence accounted for USD 105.7 million in 2025 and remains the category's central application. Demand is tied to recurrent leakage management in inpatient, post-acute, and home-care settings, where an external device can support dryness and reduce handling of absorbent products.
Urinary retention represented USD 73.7 million in 2025. External systems do not resolve retention itself, but they may support selected patients with concomitant leakage, post-void dribbling, or temporary urine-management needs where indwelling placement is not clinically necessary. This limits the segment's expansion relative to incontinence-focused applications.
Post-surgical recovery generated USD 61.4 million in 2025. Hospitals and ambulatory surgical centers use external collection options where temporary immobility, anesthesia recovery, or early discharge creates a need for hygienic urine management. The value proposition depends on short setup time, removal simplicity, and compatibility with patient mobilization.
Neurological disorders and other applications are shaped by functional dependence, repeated care needs, and caregiver burden. These use cases can support recurring demand, but they require careful fit assessment because mobility patterns, anatomy, skin condition, and care setting vary widely.
By End Use
Hospitals held a 45.2% share in 2025. Their leadership stems from the concentration of catheter-avoidance initiatives, perioperative care, patient immobility, and infection-prevention accountability. The segment rewards vendors able to provide clinical training, protocol support, and procurement evidence rather than a product-only proposition.
Ambulatory surgical centers generated USD 77.2 million in 2025. Fast patient turnover and short-duration urinary management favor products that can be applied and removed quickly while supporting recovery-area hygiene and discharge readiness. The segment is less dependent on long-term utilization than hospitals, but operational simplicity is a more immediate purchasing criterion.
Specialty clinics serve continence, urology, women's health, and rehabilitation pathways where patient education and product selection may influence downstream home utilization. Other end users, including home-care providers and long-term care facilities, represent a significant route to sustained use because incontinence care is recurrent and closely tied to caregiver workload.
GMI Analyst View
We estimate that the commercial center of gravity lies where single-use convenience, older-age urgency burden, and skin-compatible materials converge. Disposable products held a 92.4% share in 2025, while overactive bladder accounted for USD 128.5 million and silicone reached USD 122.6 million. These positions are mutually reinforcing: high-frequency incontinence management favors products that avoid cleaning burdens, and older users with urgency or mixed symptoms often require solutions compatible with dependent-care workflows.
Material selection is becoming an evidence-led differentiator rather than a secondary design choice. Pure silicone demonstrated lower bacterial colonization and biofilm-forming characteristics than silicone-coated latex in a prospective study, while the broader clinical literature identifies allergy and bacterial-adherence concerns for latex-based catheter materials,. Although those findings originate in indwelling-catheter research and should not be overstated as direct external-device outcomes, they strengthen the rationale for silicone-centered external designs where prolonged skin contact and hygiene concerns shape purchasing.
Segment leaders will not win through broad category presence alone. Suppliers need distinct propositions for acute-care catheter avoidance, home-based urgency management, and short-stay post-surgical use. A product that performs well in a hospital protocol may not meet the fit, discretion, or caregiver-handling requirements that determine repeat demand outside the facility.
U.S. Female External Catheter Market Regional Analysis
East North Central
The East North Central market is supported by a substantial concentration of hospital systems, post-acute care providers, and aging populations across Illinois, Indiana, Michigan, Ohio, and Wisconsin. Utilization is likely to be shaped by institutional catheter-reduction initiatives and the ability of providers to standardize external-device protocols across acute and post-acute settings. Suppliers require broad distribution coverage and clinical education capabilities because purchasing decisions are often system-level rather than facility-specific.
West South Central
West South Central demand is influenced by large and geographically dispersed care networks across Texas, Oklahoma, Arkansas, and Louisiana. Home health, long-term care, and hospital discharge pathways are important channels because access and caregiver availability can vary significantly between urban and rural markets. Products that are easy to train, deliver, and reorder are likely to have greater commercial relevance than highly specialized systems requiring intensive onsite support.
South Atlantic
The South Atlantic region accounted for 21% of the U.S. market in 2025 and generated USD 64.5 million. Its scale reflects an aging population, large retirement communities, and substantial demand for home-based and long-term continence care. The South also carried the largest absolute burden of overactive bladder cases among Medicare fee-for-service beneficiaries in the referenced regional analysis, at 915,091 cases. This combination favors manufacturers that can integrate hospital, skilled-care, and home-care distribution rather than rely solely on acute-care accounts.
Northeast
The Northeast generated USD 52 million in 2025. It combines dense health-system infrastructure with the highest overactive bladder prevalence in the Medicare fee-for-service regional analysis, at 8.4% and approximately 508,500 cases. Medicare coverage for qualifying permanent urinary incontinence creates a relevant reimbursement pathway across the region,. Commercial execution depends on navigating concentrated purchasing organizations, discharge-management teams, and established home-health channels.
East South Central
East South Central demand is anchored in hospital, skilled nursing, and home-care needs across Alabama, Kentucky, Mississippi, and Tennessee. Care-setting prevalence data indicate that incontinence becomes more operationally significant where beneficiaries require home-health or skilled-care support. Product uptake in this zone will depend on whether suppliers can make the value proposition practical for budget-sensitive facilities managing high caregiver workloads.
West North Central
The West North Central market is dispersed across a mix of metropolitan and rural care environments. Long travel distances and fragmented provider networks elevate the importance of distributor reach, dependable replenishment, and straightforward caregiver instruction. Suppliers that combine a clinically credible product with flexible logistics may be better positioned than those relying on intensive direct-sales support.
Pacific Central
Pacific Central generated USD 62.6 million in 2025. The zone's advanced provider base and concentration of medical-technology adoption support demand for products positioned around comfort, antimicrobial design considerations, and catheter-avoidance protocols. Regional utilization evidence also shows that non-ICU indwelling-catheter utilization was highest in the West among the four broad U.S. regions assessed, indicating a potentially important catheter-substitution opportunity where appropriate. The commercial requirement is to demonstrate operational outcomes in sophisticated health systems that expect clinical evidence and implementation support.
Mountain States
Mountain States demand is shaped by lower population density, a mix of urban referral centers and rural facilities, and the need for reliable access across dispersed geographies. Home-based care and post-acute pathways can be particularly important where travel and staffing constraints complicate repeated facility-based management. Market development will depend on distributor availability, clinician education, and products that retain performance across decentralized care settings.
GMI Analyst View
In our view, regional concentration reflects more than population size. South Atlantic's USD 64.5 million market and 21% share are supported by a large older-adult care base and the South's high absolute overactive bladder case count among Medicare beneficiaries. The commercial priority is broad continuity of care: a manufacturer that wins a hospital account but lacks home-health and long-term-care fulfillment risks losing recurrent disposable demand after discharge.
The Northeast presents a different opportunity. Its higher Medicare overactive bladder prevalence density, combined with an established reimbursement pathway for eligible permanent-incontinence patients, supports targeted clinical and payer-navigation programs rather than undifferentiated geographic expansion,,. Manufacturers should focus on health-system protocols and home-care partners capable of converting covered patients into sustained use.
Pacific Central requires a more evidence-intensive approach. The region's USD 62.6 million market, innovation-oriented provider environment, and the West's higher non-ICU catheter utilization point toward a catheter-substitution opportunity, but sophisticated customers are likely to demand credible clinical implementation support. Channel investment should therefore vary by zone: integrated care-continuum coverage in the South Atlantic, reimbursement and account concentration in the Northeast, and demonstrable workflow performance in Pacific Central.
U.S. Female External Catheter Market Share & Competitive Landscape
Competition is shaped by product comfort, urine-capture reliability, skin compatibility, infection-control positioning, clinical education, and distribution reach. Established suppliers benefit from hospital relationships and supply-chain access, while newer or specialized participants can differentiate through fit, material innovation, sustainability, or focused care-setting strategies.
Becton, Dickinson and Company
Becton, Dickinson and Company is positioned through clinical product innovation, hospital penetration, clinician relationships, and integrated urinary-management capabilities. Its scale supports participation in system-level purchasing conversations where external catheter use is evaluated alongside catheter reduction, infection prevention, and nursing workflow requirements.
BOEHRINGER
BOEHRINGER participates in a market where focused product positioning and channel access can matter as much as scale. Its competitive relevance depends on serving defined clinical or care-delivery needs without relying on broad category commoditization.
consure MEDICAL
consure MEDICAL is positioned to compete through differentiated continence-management concepts and targeted innovation. In a category where fit and capture performance strongly influence repeat use, specialized product development can create openings in care settings not fully served by standard external systems.
Hollister
Hollister's market position is supported by patient-centered design, comfort-oriented materials, education-led adoption, and relevance in home healthcare and specialty-care channels. Caregiver support and portfolio breadth are particularly important where product success depends on correct use after discharge rather than solely on hospital procurement.
Medline
Medline's distribution capabilities and relationships across acute, post-acute, and long-term care are strategically relevant to disposable external catheter adoption. The category's recurring-use profile favors suppliers that can combine product availability with dependable replenishment across multiple points of care.
Stryker
Stryker's PrimaFit platform is positioned around external urine management for female patients in acute-care environments. Product updates announced in January 2022 included longer flexible tubing, an additional 14% of ultra-soft fabric, and a tapered end, reflecting competition around comfort, positioning flexibility, and nursing workflow support.
tilla care
tilla care competes in a category where user experience and targeted continence support can differentiate smaller participants. Commercial traction depends on whether product design addresses clinically meaningful issues such as fit, dignity, skin-contact comfort, and caregiver handling.
Ur24Technology
Ur24Technology is positioned within the external urine-management field through specialized product development and focused category participation. Its competitive opportunity lies in meeting specific clinical or patient-use requirements that may be less effectively addressed by broad portfolio suppliers.
Wellspect HealthCare
Wellspect HealthCare expanded its U.S. female external catheter presence with the January 2026 launch of the Surity Female External Catheter. The launch increases competitive emphasis on external collection solutions designed for non-invasive urine management and reinforces the category's movement toward clinically differentiated alternatives to indwelling catheter use.
Recent Industry Developments
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →